Science:Life Sciences
The growing convergence of information technology and biotechnology are creating a compelling new group of companies that live in both these worlds at once. Lux Capital, which has long invested in both sectors, has a growing portfolio of these emerging TechBio companies. We spoke to Adam Goulburn, partner at Lux Capital, about his investment process, how he tempers the promise of technology with management realities and market timelines, and the changing landscape for venture investing.
view more
More Episodes
Democratizing Drug Discovery
2021-09-30
2021-09-30
Scaling Genetic Counseling Services with AI
2021-09-23
2021-09-23
Striking Hepatitis B at Its Core
2021-09-02
2021-09-02
Building a Better Path to Neurotherapeutics
2021-08-12
2021-08-12
Engineering Life to Reach New Worlds
2021-07-29
2021-07-29
Mapping the Universe of Human Proteins
2021-07-15
2021-07-15
A Test for Data-Driven Drug Development
2021-06-10
2021-06-10
Get this podcast on your
phone, FREE
